PRP for Hair Loss: Does It Work, and Is It Worth the Cost?

If you’ve looked into hair-loss treatments past minoxidil and finasteride, platelet-rich plasma (PRP) is probably the next thing that came up. Most major hair clinics offer it. The pitch is appealing: your own blood, spun down, concentrated, and injected into the scalp to “wake up” struggling follicles. Visible regrowth in three to six months. Sessions typically run $400 to $1,500.

The evidence is more mixed than the marketing suggests, and the cost is high relative to the alternatives. Here is what the published trials actually show, who responds best, and how PRP fits alongside the cheaper interventions that have stronger data.

What PRP actually is

PRP is the plasma fraction of your own blood, with platelets concentrated several times above their baseline blood concentration. The clinician draws a small volume of blood (10 to 60 mL), centrifuges it to separate plasma from red and white cells, and discards the layers that are not platelet-rich. The result is roughly 3 to 8 mL of plasma containing platelets at 3 to 5 times normal blood concentration⁷ .

Platelets are not just for clotting. When activated, they release a cocktail of growth factors: platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF-β), insulin-like growth factor 1 (IGF-1), epidermal growth factor (EGF), and fibroblast growth factor (FGF). Several of these signal hair-follicle dermal papilla cells to proliferate and prolong the anagen (growth) phase. That is the proposed mechanism for the hair-regrowth effect.

The clinician injects the concentrate into the scalp at the level of the hair-follicle bulge, typically with a fine needle in a grid pattern across the thinning area. Some protocols also activate the platelets with calcium chloride immediately before injection to trigger release of the growth factors; others rely on activation by collagen exposure once injected.

Two important variables in PRP preparations:

• Platelet concentration. Trials showing positive results typically use preparations at roughly 5 times baseline platelet count. Lower concentrations (1 to 3 times) often show no benefit, and that variation explains some of the inconsistency between studies.
• Leukocyte content. Pure PRP (P-PRP, white-cell-depleted) shows more consistent effects in hair-loss trials than leukocyte-rich PRP (L-PRP), which carries more inflammatory cells. Most dermatology practices now use P-PRP preparations for scalp work.

What the trials actually show

The evidence base is a mix of randomised half-head studies (where each patient gets PRP on one side and saline or no treatment on the other), small open-label studies, and a few meta-analyses pooling them together.

The positive trials

The pivotal randomised study is Gentile et al. 2015, a half-head trial in 23 men with androgenetic alopecia. Patients received PRP on one side of the scalp and saline placebo on the other, for 3 monthly sessions, with follow-up at 3, 6, 12, and 24 months¹ :

• At 3 months: the PRP-treated half showed an average increase of about 33 hairs/cm² versus control side.
• At 6 months: the gain was sustained at roughly 30 hairs/cm² over control.
• By month 12: the differential narrowed as the placebo side continued its baseline trajectory but the PRP side did not gain further without additional sessions.

Alves and Grimalt 2016 ran a similar half-head design with 25 patients of both sexes over 6 months and reported a smaller but statistically significant gain (around 13 hairs/cm² over control) in the PRP-treated half² .

Gupta and Carviel’s 2017 meta-analysis pooled 6 controlled trials (n = 177) and found an average gain of about 17 to 18 hairs/cm² favouring PRP over control³ . A larger 2019 meta-analysis of 19 studies similarly found PRP effective for hair density in androgenetic alopecia, with the caveat that the included trials were heterogeneous in protocol and quality⁴ .

The negative trials

Mapar et al. 2016 ran a half-head trial in 19 men with male-pattern hair loss with 3 monthly PRP sessions and a 3-year follow-up. They found no statistically significant difference between the PRP-treated and control sides at any time point⁵ . The platelet concentration in this study was lower than in the positive trials, which is one likely explanation for the discrepancy.

Several other small trials sit in between, with non-significant trends or modest effects that did not survive correction for multiple comparisons.

The honest summary

PRP works in some hands and some preparations but not all. The variance between trials is real. Two factors explain most of it:

1. Platelet concentration. Higher (around 5x baseline) gets better results.
2. Patient selection. Early-to-moderate androgenetic alopecia (Norwood II-IV in men, Sinclair 2-4 in women) responds better than advanced loss, where most follicles are already dormant or scarred.

If a clinic does not measure or report platelet concentration in their preparations, you are paying for an unstandardised treatment.

PRP for alopecia areata

Smaller body of evidence, but Trink et al. 2013 ran a half-head trial in 45 patients with alopecia areata and found PRP outperformed both topical triamcinolone and placebo for regrowth at 12 months⁶ . PRP can be a reasonable add-on for patchy alopecia areata when first-line treatments have failed, but it is not a substitute for systemic therapy in severe cases.

The protocol

A typical evidence-based PRP protocol for androgenetic alopecia:

• Induction phase: 3 to 4 sessions, spaced 4 to 6 weeks apart.
• Maintenance phase: 1 session every 3 to 6 months indefinitely.
• Visible response timing: earliest changes at 3 months, peak effect around 6 months from starting, gradual decline over 6 to 12 months without maintenance.
• Volume per session: 3 to 8 mL of PRP, injected as 30 to 60 small intradermal aliquots across the thinning area.

Stopping sessions reverses the effect over 6 to 12 months. PRP is not a one-time procedure with permanent results; it is more like a recurring treatment, similar to topical minoxidil in that respect.

Cost

PRP is the most expensive non-surgical hair-loss treatment in routine use. Pricing varies by region and clinic positioning:

• Per session: $400 to $1,500 in the US, often higher at premium dermatology or hair-restoration clinics. Roughly $300 to $900 in most of Europe.
• Annual cost (induction + maintenance): $1,500 to $5,000 typically, sometimes more.
• 5-year cost: in the range of $7,500 to $25,000.

For comparison, generic finasteride 1 mg/day is around $10 to $15 per month with a prescription (roughly $150 a year, $750 over 5 years), and topical minoxidil is $10 to $30 per month. PRP is one to two orders of magnitude more expensive than the FDA-approved drug treatments.

How PRP compares to alternatives

The pattern that emerges: PRP delivers a modest, reversible boost at 5 to 30 times the cost of the FDA-approved alternatives, and the alternatives have substantially stronger evidence. PRP makes more sense as a third-line addition for someone already on the basics than as a starting treatment.

Side effects and risks

PRP uses your own blood, so allergic reactions and disease transmission are essentially impossible. The real risks are local:

• Injection site pain. Most patients report 4 to 7 out of 10 pain during injection. Topical anaesthetic (lidocaine cream) applied 30 to 60 minutes before reduces this substantially.
• Bruising and swelling. Common, usually resolves in 2 to 5 days.
• Headache. Reported in about 10 to 15% of patients in the 24 hours after a session, usually mild.
• Vasovagal response. Some patients faint or feel lightheaded during injection. Lying down during the procedure helps.
• Infection. Rare with proper sterile technique. Higher risk if the patient skips post-procedure scalp hygiene guidance or has active dermatitis.
• No response. A meaningful fraction of patients do not respond, even with adequate platelet concentration. There is no reliable way to predict non-response in advance, which is the financial risk of starting.

PRP should generally be avoided in patients with active scalp infections, bleeding disorders or anticoagulant therapy without coordination with the prescribing doctor, active scarring alopecia (where it can accelerate inflammation), and anyone with hematologic conditions affecting platelet function.

Who PRP is right for

PRP makes the most sense for:

• Early-to-moderate androgenetic alopecia (Norwood II-IV men, Sinclair 2-4 women) who are already on minoxidil and finasteride and want a third intervention to push response further.
• People who do not tolerate finasteride and are looking for non-pharmacological options to add to topical minoxidil.
• Patchy alopecia areata that has not responded to first-line corticosteroids.
• Patients with the budget for sustained treatment. The cost is the binding constraint for most people.

PRP makes less sense for:

• First-line treatment in someone who has not tried minoxidil or finasteride. The cost-to-evidence ratio is wrong; start with the cheaper, better-studied options.
• Advanced androgenetic alopecia (Norwood V+, Sinclair 5+). Most follicles are already dormant or scarred, and PRP cannot revive them. A transplant evaluation is the right move at that stage.
• Anyone with active scarring alopecia or alopecia areata totalis/universalis. Different mechanism, different treatment.

When to see a dermatologist

• Before starting PRP, especially if your diagnosis is not clearly androgenetic alopecia. Microneedling and PRP can both worsen scarring alopecias and active alopecia areata.
• If you have been getting PRP sessions for 6+ months alongside minoxidil with no visible improvement. Adjust the protocol or consider that you may be in the non-responder group.
• If you experience signs of infection at injection sites: increased redness 24+ hours later, warmth, pus, fever.
• If you are considering combining PRP with microneedling, oral medications, or hair transplantation, where coordination matters for outcomes and timing.

What this article does not cover

We have focused on PRP for androgenetic alopecia in adults, with brief coverage of alopecia areata. We have left out detailed coverage of PRP for scarring alopecias (limited evidence, individual patient assessment required), paediatric use (insufficient data), and PRP combined with mesotherapy or exosome injections (newer, smaller evidence base). Hair transplantation with intra-operative PRP (where surgeons inject PRP into transplanted grafts during or after the procedure) is also a separate topic with its own literature.

If you are considering PRP and you are not sure your diagnosis is androgenetic alopecia, talk to a dermatologist before booking sessions. Anything in this article is general education, not personal medical advice.